SCHEMBL11536711

SCHEMBL11536711

Cc1cc(C(=O)CCC(=O)O)ccc1Cl

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.58
USP5 P45974 1/20 0.53
CYP1A2 P05177 4/20 0.50
CYP2C19 P33261 3/20 0.50
ALDH1A1 P00352 3/20 0.50
HPGD P15428 1/20 0.50
HSD17B10 Q99714 1/20 0.50
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
MCL1 Q07820 1/20 0.49
NR4A2 P43354 1/20 0.48
PKM P14618 1/20 0.47
TSHR P16473 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 1/20 0.47
FFAR1 O14842 1/20 0.47
LMNA P02545 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HIF1A Q16665 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10598079 0.86 KMT2A (0.58) KMT2AUSP5CYP1A2CYP2C19ALDH1A1
SCHEMBL24404054 0.86 KDM4E (0.54) KMT2ACYP1A2CYP2C19ALDH1A1HPGD
SCHEMBL6279999 0.84 CYP1A2 (0.50) CYP1A2CYP2C19ALDH1A1CYP3A4CYP2C9
SCHEMBL5081102 0.84 KMT2A (0.63) KMT2AUSP5CYP1A2CYP2C19ALDH1A1
SCHEMBL727064 0.84 TSHR (0.59) KMT2AUSP5CYP1A2NR4A2PKM
SCHEMBL24403937 0.83 MAOA (0.53) KMT2AUSP5CYP1A2CYP2C19CYP3A4
SCHEMBL8214726 0.81 KMT2A (0.59) KMT2AUSP5CYP1A2CYP2C19ALDH1A1
SCHEMBL11637468 0.81 USP5 (0.50) KMT2AUSP5CYP1A2CYP2C19ALDH1A1
SCHEMBL2278168 0.80 CYP3A4 (0.52) CYP1A2CYP2C19ALDH1A1HPGDCYP3A4
SCHEMBL2097486 0.80 GSK3B (0.53) CYP1A2CYP2C19ALDH1A1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240182452-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-06-06 US disclosed
US-11897867-B2 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer BAYER AKTIENGESELLSCHAFT (DE) 2024-02-13 US disclosed
EP-3661917-B1 6-((3-TRIFLUOROMETHYL)PHENYL)-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AG (DE) 2022-05-11 EP disclosed
US-20200247783-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2020-08-06 US disclosed
US-20200247783-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2020-08-06 US disclosed
EP-3661917-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER Bayer Aktiengesellschaft (DE) 2020-06-10 EP disclosed
WO-2019025554-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2019-02-07 WO disclosed
WO-2019025554-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2019-02-07 WO disclosed
US-4136184-A TRANQUILIZERS, ANTICONVULSANTS, MUSCLE RELAXANTS SANDOZ, INC. (US) 1979-01-23 US disclosed
US-4055644-A CNS DEPRESSANTS SANDOZ, INC. (US) 1977-10-25 US disclosed
US-3947460-A SEDATIVES-HYPNOTIC, TRANQUILIZER SANDOZ, INC. (US) 1976-03-30 US disclosed
US-3931176-A CNS DEPRESSANT SANDOZ INC. (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182452-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER PDE3A, PDE3B, PDE5A KMT2A 1155/4885USP5 1141/4885CYP1A2 365/4885
US-20200247783-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER PDE3B, PDE3A, PDE5A KMT2A 656/4885USP5 579/4885CYP1A2 262/4885
US-11897867-B2 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer PDE3B, PDE3A, PDE5A KMT2A 656/4885USP5 579/4885CYP1A2 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.